Acumen Pharmaceuticals, Inc.
ABOS
$2.41
$0.010.42%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 101.61% | -390.57% | |||
| Gross Profit | -101.61% | 390.57% | |||
| SG&A Expenses | -0.17% | 2.82% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -16.07% | -4.96% | |||
| Operating Income | 16.07% | 4.96% | |||
| Income Before Tax | 17.51% | 4.96% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 17.51% | 4.96% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 17.51% | 4.96% | |||
| EBIT | 16.07% | 4.96% | |||
| EBITDA | 16.08% | 4.95% | |||
| EPS Basic | 20.96% | 4.97% | |||
| Normalized Basic EPS | 20.97% | 4.95% | |||
| EPS Diluted | 20.96% | 4.97% | |||
| Normalized Diluted EPS | 20.97% | 4.95% | |||
| Average Basic Shares Outstanding | 4.37% | 0.00% | |||
| Average Diluted Shares Outstanding | 4.37% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||